(CNC) Centene - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US15135B1017

Medicaid, Medicare, Commercial, Pharmacy, Clinical

Managed Health Care
Market Cap in USD: 22,910m
IPO / Inception: 2001-12-13
12m vs SPY: -36.7%

EPS (Earnings per Share)

EPS (Earnings per Share) of CNC over the last years for every Quarter: "2020-12": 0.46, "2021-03": 1.63, "2021-06": 1.25, "2021-09": 1.26, "2021-12": 1.01, "2022-03": 1.83, "2022-06": 1.77, "2022-09": 1.3, "2022-12": 0.86, "2023-03": 2.11, "2023-06": 2.1, "2023-09": 2, "2023-12": 0.45, "2024-03": 2.26, "2024-06": 2.42, "2024-09": 1.62, "2024-12": 0.8, "2025-03": 2.9, "2025-06": -0.51, "2025-09": 0.5, "2025-12": 0,
EPS CAGR: -29.42%
EPS Trend: -48.5%
Last SUE: 3.14
Qual. Beats: 2

Revenue

Revenue of CNC over the last years for every Quarter: 2020-12: 28288, 2021-03: 29983, 2021-06: 31025, 2021-09: 32406, 2021-12: 32568, 2022-03: 37185, 2022-06: 35936, 2022-09: 35865, 2022-12: 35561, 2023-03: 38889, 2023-06: 37608, 2023-09: 38042, 2023-12: 39460, 2024-03: 40407, 2024-06: 39836, 2024-09: 42023, 2024-12: 40805, 2025-03: 46620, 2025-06: 48742, 2025-09: 49690, 2025-12: null,
Rev. CAGR: 11.93%
Rev. Trend: 92.7%
Last SUE: 1.81
Qual. Beats: 11

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 49.7%
Value at Risk 5%th 67.9%
Relative Tail Risk -16.87%
Reward TTM
Sharpe Ratio -0.26
Alpha -34.06
CAGR/Max DD -0.22
Character TTM
Hurst Exponent 0.415
Beta 0.152
Beta Downside 0.143
Drawdowns 3y
Max DD 68.65%
Mean DD 21.64%
Median DD 15.43%

Description: CNC Centene December 19, 2025

Centene Corp (NYSE:CNC) is a U.S.-based managed-care company that serves under-insured and uninsured populations through four business lines: Medicaid (including TANF, Medicaid expansion, and dual-eligible plans), Medicare (special-needs, supplement, and prescription-drug plans), Commercial (individual and group marketplace products), and “Other” (clinical services, pharmacy, vision/dental, behavioral health, and federal contracts). Founded in 1984 and headquartered in St. Louis, Missouri, the firm leverages a network of primary-care, specialty-care, hospital, and ancillary providers to deliver health-benefit solutions.

Key recent metrics: 2023 revenue reached approximately $140 billion, with Medicaid enrollment up ~4% YoY driven by continued state expansions, while Medicare Advantage enrollment grew ~7% as seniors shift to managed-care plans. The sector is sensitive to federal policy-particularly ACA marketplace subsidies and Medicaid funding reforms-which together account for roughly 70% of Centene’s revenue mix. Operating margin has hovered near 3% after integrating several recent acquisitions, reflecting both scale benefits and integration costs.

If you want a data-rich, independent assessment of CNC’s valuation, ValueRay’s analyst notes provide a concise starting point for further research.

Piotroski VR‑10 (Strict, 0-10) 4.5

Net Income (-5.29b TTM) > 0 and > 6% of Revenue (6% = 11.15b TTM)
FCFTA 0.04 (>2.0%) and ΔFCFTA 3.79pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 1.85% (prev 2.07%; Δ -0.22pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.05 (>3.0%) and CFO 4.06b > Net Income -5.29b (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 1.08 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (491.1m) change vs 12m ago -6.19% (target <= -2.0% for YES)
Gross Margin 10.76% (prev 10.37%; Δ 0.40pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 226.1% (prev 196.4%; Δ 29.66pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -6.09 (EBITDA TTM -2.90b / Interest Expense TTM 682.0m) >= 6 (WARN >= 3)

Altman Z'' 0.49

(A) 0.04 = (Total Current Assets 44.06b - Total Current Liabilities 40.63b) / Total Assets 82.09b
(B) 0.12 = Retained Earnings (Balance) 9.78b / Total Assets 82.09b
(C) -0.05 = EBIT TTM -4.16b / Avg Total Assets 82.22b
(D) 0.16 = Book Value of Equity 9.68b / Total Liabilities 61.03b
Total Rating: 0.49 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 44.14

1. Piotroski 4.50pt
2. FCF Yield 14.32%
3. FCF Margin 1.81%
4. Debt/Equity 0.84
5. Debt/Ebitda -0.18
6. ROIC - WACC (= -11.35)%
7. RoE -20.61%
8. Rev. Trend 92.73%
9. EPS Trend -48.47%

What is the price of CNC shares?

As of January 16, 2026, the stock is trading at USD 46.17 with a total of 3,683,059 shares traded.
Over the past week, the price has changed by +0.75%, over one month by +16.86%, over three months by +32.08% and over the past year by -25.15%.

Is CNC a buy, sell or hold?

Centene has received a consensus analysts rating of 3.89. Therefore, it is recommended to buy CNC.
  • Strong Buy: 7
  • Buy: 3
  • Hold: 9
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the CNC price?

Issuer Target Up/Down from current
Wallstreet Target Price 43.1 -6.7%
Analysts Target Price 43.1 -6.7%
ValueRay Target Price 46.5 0.7%

CNC Fundamental Data Overview January 10, 2026

P/E Forward = 15.6495
P/S = 0.1366
P/B = 1.1009
P/EG = 1.9309
Revenue TTM = 185.86b USD
EBIT TTM = -4.16b USD
EBITDA TTM = -2.90b USD
Long Term Debt = 17.55b USD (from longTermDebt, last quarter)
Short Term Debt = 38.0m USD (from shortTermDebt, last quarter)
Debt = 17.58b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 525.0m USD (from netDebt column, last quarter)
Enterprise Value = 23.43b USD (22.91b + Debt 17.58b - CCE 17.06b)
Interest Coverage Ratio = -6.09 (Ebit TTM -4.16b / Interest Expense TTM 682.0m)
EV/FCF = 6.98x (Enterprise Value 23.43b / FCF TTM 3.36b)
FCF Yield = 14.32% (FCF TTM 3.36b / Enterprise Value 23.43b)
FCF Margin = 1.81% (FCF TTM 3.36b / Revenue TTM 185.86b)
Net Margin = -2.85% (Net Income TTM -5.29b / Revenue TTM 185.86b)
Gross Margin = 10.76% ((Revenue TTM 185.86b - Cost of Revenue TTM 165.85b) / Revenue TTM)
Gross Margin QoQ = 16.38% (prev 6.05%)
Tobins Q-Ratio = 0.29 (Enterprise Value 23.43b / Total Assets 82.09b)
Interest Expense / Debt = 0.97% (Interest Expense 170.0m / Debt 17.58b)
Taxrate = 22.62% (963.0m / 4.26b)
NOPAT = -3.22b (EBIT -4.16b * (1 - 22.62%)) [loss with tax shield]
Current Ratio = 1.08 (Total Current Assets 44.06b / Total Current Liabilities 40.63b)
Debt / Equity = 0.84 (Debt 17.58b / totalStockholderEquity, last quarter 20.95b)
Debt / EBITDA = -0.18 (negative EBITDA) (Net Debt 525.0m / EBITDA -2.90b)
Debt / FCF = 0.16 (Net Debt 525.0m / FCF TTM 3.36b)
Total Stockholder Equity = 25.67b (last 4 quarters mean from totalStockholderEquity)
RoA = -6.43% (Net Income -5.29b / Total Assets 82.09b)
RoE = -20.61% (Net Income TTM -5.29b / Total Stockholder Equity 25.67b)
RoCE = -9.62% (EBIT -4.16b / Capital Employed (Equity 25.67b + L.T.Debt 17.55b))
RoIC = -7.36% (negative operating profit) (NOPAT -3.22b / Invested Capital 43.67b)
WACC = 3.99% (E(22.91b)/V(40.49b) * Re(6.48%) + D(17.58b)/V(40.49b) * Rd(0.97%) * (1-Tc(0.23)))
Discount Rate = 6.48% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -4.42%
[DCF Debug] Terminal Value 81.90% ; FCFF base≈2.11b ; Y1≈1.48b ; Y5≈773.5m
Fair Price DCF = 48.41 (EV 24.32b - Net Debt 525.0m = Equity 23.80b / Shares 491.5m; r=5.90% [WACC]; 5y FCF grow -34.97% → 2.90% )
[DCF Warning] FCF declining rapidly (-34.97%), DCF may be unreliable
EPS Correlation: -48.47 | EPS CAGR: -29.42% | SUE: 3.14 | # QB: 2
Revenue Correlation: 92.73 | Revenue CAGR: 11.93% | SUE: 1.81 | # QB: 11
EPS next Quarter (2026-03-31): EPS=2.08 | Chg30d=-0.146 | Revisions Net=+4 | Analysts=14
EPS next Year (2026-12-31): EPS=2.94 | Chg30d=+0.019 | Revisions Net=-1 | Growth EPS=+44.5% | Growth Revenue=+0.1%

Additional Sources for CNC Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle